Product Information
LUBIPROSTONE 8 MCG CAPSULE is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.5493 per EA under NDC 70710164106. Its NADAC has been published 140 times since Dec 20, 2023.
FDA first approved this application on Mar 23, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 ug/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710164106
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LUBIPROSTONEApproval Type
Generic (ANDA)
FDA Application
ANDA214131FDA Approved
3/23/2023
TE Code
AB
On Market Since
3/23/2023
Pharmacological Classes
Price Statistics
The NADAC for LUBIPROSTONE 8 MCG CAPSULE has been published 140 times since Dec 20, 2023, and over the history we have for it it has declined 56.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5493 per EA |
|---|---|
| All-time high | $1.2567 (Jan 10, 2024) |
| All-time low | $0.5447 (Nov 20, 2024) |
| 52-week high | $0.8252 |
| 52-week low | $0.5493 |
| Median price | $0.7498 |
| Average price | $0.7612 |
| Largest weekly change | +39.5% (Jun 19, 2024) |
| Weeks tracked | 140 |
| Tracking since | Dec 20, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LUBIPROSTONE 8 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LUBIPROSTONE 8 MCG CAPSULE, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.5493 per EA (NDC 70710164106), effective Aug 19, 2026.
How has the price of LUBIPROSTONE 8 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has declined 56.3%. It has been tracked across 140 weekly CMS publications since Dec 20, 2023.
What are the highest and lowest recorded NADAC prices for LUBIPROSTONE 8 MCG CAPSULE?
Since Dec 20, 2023, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has ranged from a low of $0.5447 (Nov 20, 2024) to a high of $1.2567 (Jan 10, 2024), with a median of $0.7498 per EA.
Are there cheaper alternatives to LUBIPROSTONE 8 MCG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LUBIPROSTONE 8 MCG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LUBIPROSTONE 8 MCG CAPSULE?
LUBIPROSTONE 8 MCG CAPSULE (NDC 70710164106) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.